canakinumab
canakinumab: developed by 1 company · 7 clinical trials tracked · 1 FDA decision.
canakinumab evidence translation
What we can confirm
1 FDA record · 7 tracked trials
What it means
What to watch
Prepared research question
How could canakinumab → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (3)
| Company | Phase |
|---|---|
| Novartis AG (NVS) Hereditary Periodic Fever Syndromes | Phase 4 |
| Novartis AG (NVS) Mild Cognitive Impairment; Non-small Cell Lung Cancer | Phase 4 |
| Novartis AG (NVS) Mild Cognitive Impairment; Non-small Cell Lung Cancer; Adult… | Phase 4 |
Clinical Trials (7)
Real Life Non-interventional Study on Safety and Effectiveness of Ilaris® (Canakinumab) 150 mg for Subcutaneous Injection in Hereditary Periodic Fever Syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) Patients and sJIA Patients (REASSURE)
Primary endpoint: Incidence of adverse events and serious adverse events
Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer's Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory Agents in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Primary endpoint: Change From Baseline in Cognition as Measured by the Neuropsychological Test Battery (NTB) Z-scores
Phase I/II Study of Canakinumab With Chemoradiation and Durvalumab for Unresected Locally-Advanced Non-Small Cell Lung Cancer (CHORUS)
Primary endpoint: progression-free survival
An Open-label, Single-arm, Active-treatment Study to Evaluate Efficacy and Safety of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Adult Onset Still's Disease (AOSD)
Primary endpoint: Percentage of Participants Who Achieved Adapted American College of Rheumatology (ACR) 30 Response at Week 8
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Primary endpoint: Hematological improvement (HI)
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
Primary endpoint: Percentage of subjects who proceed to radical nephrectomy
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Primary endpoint: Part 1 (Safety Run-in): Number of Participants With Dose-limiting Toxicities (DLTs)
FDA Decisions1 records
Frequently asked questions
Who is developing canakinumab?
canakinumab is being developed by Novartis AG.
How many clinical trials involve canakinumab?
BioSniper tracks 7 clinical trials involving canakinumab.
What is canakinumab's latest FDA decision?
The most recent tracked FDA decision for canakinumab is Approval, dated June 17, 2009.